[1]
G. Masi, “Bevacizumab beyond progression: Pros”,
Eur J Oncol Env Hea
, vol. 19, no. 1S, pp. 33–35, Mar. 2014, Accessed: May 03, 2025. [Online]. Available:
https://mattioli1885journals.com/index.php/EJOEH/article/view/4260